Phase II Study of Irinotecan Plus Cisplatin as First Line therapy in Extensive Small-Cell Lung Cancer.
10.4046/trd.2006.61.2.143
- Author:
Ki Eun HWANG
1
;
So Young KIM
;
Jong Hoon JUNG
;
Seong Hoon PARK
;
Jung Hyun PARK
;
Hwi Jung KIM
;
Hak Ryul KIM
;
Sei Hoon YANG
;
Eun Taik JEONG
Author Information
1. Department of Internal Medicine, College of Medicine, Wonkwang University, Iksan, Korea. jetpul@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Small-cell lung cancer;
Irinotecan;
Cisplatin
- MeSH:
Cisplatin*;
Diarrhea;
Disease-Free Survival;
Drug Therapy;
Humans;
Leukopenia;
Lung Neoplasms*;
Lung*;
Survival Rate
- From:Tuberculosis and Respiratory Diseases
2006;61(2):143-149
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Irinotecan (topoisomerase I inhibitor) is effective as a monotherapy against small-cell lung cancer(SCLC). Cisplatin is also an important drug against SCLC. A phase II study of irinotecan combined with cisplatin was carried out to evaluate the efficacy and toxicity of this combined regimen as a first line treatment in patients with extensive SCLC. METHODS: Thirty-nine patients with previously untreated extensive SCLC were enrolled in this study. Irinotecan 60mg/m(2) was administered intravenously on days 1, 8 and 15, and in combination with cisplatin 60mg/m(2) on day 1 and every 28 days thereafter. Four cycles of chemotherapy were given to the patients. RESULTS: The overall response rate was 77% with a complete response (CR) rate of 8%. The median survival time, 1- and 2-year survival rate were 14.8 months, 60.9% and 27.6%, respectively. The median progression free survival time, 6-and 12-month progression free survival rate were 8.4 months, 75% and 18.8%, respectively. The WHO grade 3 or more toxicity encountered were leukopenia (23%), diarrhea (26%). Two patients changed their chemotherapeutic regimen and one patient died from severe diarrhea. CONCLUSION: The combination of irinotecan and cisplatin is effective as a first line therapy in extensive SCLC is effective , but has severe or fatal diarrhea as toxicity.
